Idorsia (IDIA) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic overview and leadership

• New CEO presented a focused strategy to commercialize two key assets and advance a robust pipeline, leveraging legacy expertise from Actelion.

• Emphasis on disciplined execution and value creation for both patients and shareholders, with forward-looking statements for 2026.

• Focus on two products with blockbuster potential and a robust pipeline of first- or best-in-class drugs.

• Strategic alliances and global partnerships drive expansion and access to new markets.

• Financially positioned for growth with a cash runway into 2028 and on-track to deliver 2025 guidance.

Product highlights and market opportunities

• QUVIVIQ (daridorexant) is the only therapy to show improvement in daytime functioning for insomnia, with global label inclusion except in the U.S.

• Rapid global expansion of QUVIVIQ, with approvals and launches in the US, EU, Japan, China, and other regions; over 100,000 patients in China post-launch.

• TRYVIO (aprocitentan) is the first dual ERA approved for systemic hypertension, targeting a multi-billion dollar market and addressing a major public health issue with 1.4 billion global patients.

• TRYVIO demonstrates strong efficacy and safety, with positive feedback from top hypertension centers and a path to $5B peak sales.

• Both products are entering a value-acceleration phase, with clear paths to blockbuster scale.

Pipeline and innovation

• Two late-stage assets with Viatris: selatogrel (acute MI) and cenerimod (systemic lupus), both in Phase III with milestone/royalty structure.

• Lucerostat for Fabry disease offers a mutation-independent oral alternative, with promising secondary endpoints and upcoming data, targeting a $4B market.

• Early-stage pipeline includes chemokine receptor antagonists for psoriasis, progressive MS, and vitiligo, with new trials starting in 2026.

• Synthetic glycan vaccine platform targets C. difficile and other MDR bacteria, with proof-of-concept and dose-dependent immunogenicity.

• Multiple assets are designed for multi-billion dollar peak sales potential.